Physician

Muthamma J Machimada, MD

According to 2025 Medicare claims, Muthamma Machimada, MD (NPI: 1699725986) practices rheumatology in the Greenville-Anderson-Greer, SC market, with the plurality of this provider's patient population coming from Greenville, SC. This provider's primary affiliated billing organization is BON SECOURS MEDICAL GROUP GREENVILLE SPECIALTY CARE LLC (NPI: 1821679580; TIN: 850988160) and primary practice location at 29615-5194.

Machimada's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 279 traditional Medicare patients, billed 39,469 HCPCS/CPT codes, and received $670,125 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 3,013 prescription claims across 404 beneficiaries totaling $3,205,845 in drug costs, led by Enbrel Sureclick (Etanercept). Open Payments data shows 1 records totaling $19. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $932,426 to $3,205,845. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	304	2,934	$69,562
2016	299	2,724	$69,799
2017	324	21,671	$583,147
2018	339	35,669	$826,172
2019	342	42,602	$809,533
2020	452	73,228	$1,322,447
2021	324	60,056	$961,943
2022	273	46,180	$744,933
2023	266	36,623	$680,820
2024	279	39,469	$670,125

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	429	6,277	$932,426
2016	438	6,588	$966,657
2017	456	3,462	$896,507
2018	324	2,760	$1,082,187
2019	348	2,928	$1,144,305
2020	391	3,253	$1,500,335
2021	396	3,045	$2,187,406
2022	403	3,019	$2,117,003
2023	406	2,807	$2,416,630
2024	404	3,013	$3,205,845

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	48	61	$119
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	33	33	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	231	501	$81
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	24	128	$41
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	201	286	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	127	3,948	$1,032,012
Humira(Cf) Pen	Adalimumab	90	2,984	$990,909
Humira Pen	Adalimumab	16	588	$145,721
Cimzia (2 Pack)	Certolizumab Pegol	24	672	$135,130
Enbrel	Etanercept	12	448	$116,477

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$19	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Muthamma J. Machimada, MD?

Tedicare shows public-source Medicare data for Muthamma J. Machimada, MD (NPI 1699725986), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Muthamma J. Machimada, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Muthamma J. Machimada, MD?

Muthamma J. Machimada, MD is linked to BON SECOURS MEDICAL GROUP GREENVILLE SPECIALTY CARE LLC (billing NPI 1821679580) in the available physician profile data.

Does Muthamma J. Machimada, MD have Open Payments data?

Muthamma J. Machimada, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.